|Mauna Kea Technologies SA -- France Stock|| |
EUR 2.65 0.01 0.38%
Chairman, Independent Director
Mr. Gilles Brisson was Chairman of the Board and Independent Director of Mauna Kea Technologies SA since March 5 2012. He is Member of the Company Audit Committee and Remuneration Committee. He has served in various roles during his 20year tenure at RhonePoulenc Rorer including Senior VicePresident of Corporationrationrate Development. He led Aventis French pharmaceutical business from 1999 to 2003 as President and Chief Executive Officer. Then he became Senior Vice President of Europe for Aventis and Sanofi aventis. Mr. Brisson was Chairman of the Supervisory Board of Innate Pharma since 2007 and of Ethypharm since 2009.
Age: 61 Chairman Since 2012
33 1 48 24 03 45 http://www.maunakeatech.com
The company has return on total asset (ROA)
of (29.39) %
which means that it has lost $29.39 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (77.19) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 3.04 M in total debt with debt to equity ratio (D/E) of 27.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 2.7 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Mauna Kea Technologies S.A. develops, produces, and markets microendoscopes and probes, as well as related services. Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in , rue d'EnghienParis, and employs 83 people.